The inaugural issue of Circulation Genetics arrives at a remarkable time in the history of genetic research and cardiovascular medicine. Despite the tremendous progress in knowledge, cardiovascular disease remains the leading cause of death in the United States 1 , and it has overcome infectious diseases as the leading cause worldwide. 2 In addition, rates of cardiovascular disease (CVD) remain higher in African American and Hispanic populations in the US. 1 The recent Strategic Plan of the National Heart, Lung and Blood Institute (NHLBI) emphasizes research areas to fill the significant knowledge gaps needed to improve the diagnosis, treatment and control of known risk factors and clinically apparent disease. Simultaneously, the NHLBI Strategic Plan recognizes a tremendous opportunity that is available for use of genetic and genomic research to generate new knowledge that might reduce the morbidity and mortality from CVD in US populations. 3 Public availability of vast amounts of detailed sequence information about the human genome, completed sequence data on dozens of other animal genomes, and the private sector development of high throughput genetic technologies has transformed in a few short years the conduct of cardiovascular genetics and genomics research from a primary focus on Mendelian disorders to a current emphasis on genomewide association studies (GWAS) (Figure 1 ). In this review, we describe the rationale for the current emphasis on largescale genomic studies, we summarize the evolving approaches and progress to date, and we identify immediate-term research needs. The National Institutes of Health (NIH) and the NHLBI are supporting a portfolio of largescale genetic and genomic programs in diverse US populations with the longer term objective of translating knowledge into the prediction, prevention and preemption of CVD, as well as lung, sleep, and blood disorders. Underlying this portfolio is a strong commitment to make available participant level data and aggregate research results to the broad community of investigators, while protecting the privacy and confidentiality and respecting the informed consent of study participants.
overemphasized, since the identification of rare conditions usually begins with the assembly of pedigrees in which an autosomally dominant or recessive pattern of inheritance is identified. Pedigree studies using positional cloning approaches have led to a comprehensive body of information regarding the role of deleterious mutations, often in exons (the protein coding region of human genes) leading to altered protein function or number. These studies have uncovered rare (minor allele frequency [MAF] generally << 0.1%) genetic mutations in the sequence encoding key sarcomere and storage disorder proteins underlying hypertrophic and dilated cardiomyopathy, in ion channels underlying long-QT syndrome and ventricular tachycardia, and in FBN1 underlying thoracic aortic aneurysms and aortic dissection. 4 Knowledge regarding causal mutations has contributed tremendously to our understanding of the pathophysiology of these conditions and in some cases, such as familial hypercholesterolemia, has led to the development of new treatments, such as lipid lowering drug therapies, that are now widely used in general populations. However, while genetic testing for some of the above conditions is now available in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories, in most cases there is not yet a clear role in clinical practice for the genetic testing of mutations in cardiovascular diagnosis or treatment.
One example of remarkable progress in the past several years has been our understanding of the molecular genetics of the rare, premature aging condition, Hutchinson-Gilford progeria syndrome (Progeria). Progeria results from a spontaneous, de novo point mutation in exon 11 of the LMNA gene, producing an alternatively spliced form of prelamin A, called progerin. 5 In normal cells, prelamin A undergoes a series of posttranslational modifications, including farnesylation and enzymatic cleavage of terminal 15 amino acids and the farnesyl group, allowing mature lamin A to migrate from the nuclear membrane to the nuclear lamina. In contrast, because of the alternate splicing which internally deletes 50 amino acids, progerin lacks the second cleavage site, remains permanently farnestylated, and adheres to the nuclear membrane, disrupting nuclear trafficking and lamina function. Children with progeria uniformly die of heart attack and stroke in their early to mid teens, due to a drop out of vascular smooth muscle cells (vsmcs) in the media of arteries and veins with maladaptive vascular remodeling, fibrosis and luminal narrowing. 6, 7 Treatment of progerin cells in culture and transgenic progerin mice with a farnesyl transferase inhibitor (FTI) restores nuclear architecture and function, and prevents development and progression of the vascular disease in progerin mice. 8 Accordingly, a clinical trial has been initiated to study the effect of FTI treatment on the growth curve and CV disease in children with progeria. The role of progerin on vsmc cell cycle and proliferation, progenitor cell renewal and normal aging, all features of common CV disease, are under investigation.
In contrast to rare Mendelian conditions, common, "complex" conditions underlie the continued high rates of CVD morbidity and mortality. These common CVDs include coronary heart disease, heart failure and sudden cardiac death; the well established common risk factors for CVD include hypertension, dyslipidemia, and adult onset diabetes mellitus. 9, 10 While it appears that few cases of these conditions in the general population are explained by rare Mendelian causes, there is remarkably little reliable information on the actual proportion of risk for common CVDs (ie, the attributable risk) that is conferred by rare (eg, MAF <<0.1%) versus uncommon (eg, MAF <0.1-1%) mutations versus common variants (eg, MAF ≥1%).
Recently, investigators conducted sequencing studies in general populations to have begin to estimate the contribution to common CVD risk of variants in genes known to underlie Mendelian CVD or other candidate genes. For example, a recent sequencing study of genetic variation in exons of sarcomere protein genes and storage cardiomyopathy-causing genes was conducted for determinants of increased left ventricular wall thickness in ~1800 persons from the community-based Framingham Heart Study. There were 7 mutations found in 5 sarcomere protein genes and 1 mutation in the alpha-galactosidase A (GLA) gene; at least one of these mutations was detected in 1% of all persons in the community and in 18% of person with increased left ventricular wall thickness. 11 In a separate community-based sequencing study, at least 1 out of 64 subjects was found to carry a functional mutation in one of three genes-NCCT, NKCC2 and ROMK-previously known to cause rare recessive diseases featuring large reductions in blood pressure. 12 And in a sequencing study of the adipokine ANGPTL4 gene in over 3500 subjects from the Dallas Heart Study, nonysnonymous (amino-acid altering) variants were found in 13 persons with low triglycerides versus 2 with high triglycerides, and more nonsynonymous variants were found in European Americans than in African Americans. 13 The role of human ANGPTL4 has been unknown, although in mice a genetic deletion of ANGPTL4 leads to lower plasma triglyceride levels, and overexpression of ANGPTL4 in the liver leads to hypertriglyceridemia. 13 A similar approach led to the discovery of variants of PCSK9 occurring in ~3% of the population and associated with low LDL and low risk of incident coronary heart disease. 14, 15 Reliable estimates regarding the overall contribution of rare and uncommon variants to the burden of common cardiovascular diseases awaits largescale sequencing studies of not only genes implicated in Mendelian forms of CVD but also all other known genes. Candidate gene sequencing studies are underway for CVD candidate genes supported by both the NHGRI Medical Resequencing Program 16 and the NHLBI Resequencing and Genotyping Program. 17 In a recent RFA, the NHLBI will support the development of technologies to enable the accurate, high throughput genomewide sequencing of all protein-coding gene exons and other important regulatory regions in large numbers of human subjects, with the ultimate goal of defining the association of such variants with cardiovascular, lung and blood diseases.
As we await results of sequencing studies, our estimates of the role of Mendelian versus more complex forms of inheritance in CVD derive primarily from available family history studies. One clue may be found in the results of a very large survey of 122,155 Utah families, which underscores the significant burden of familial risk to CHD and stroke but the relatively small contribution of rare conditions. A positive family history of coronary heart disease accounted for 14% of all families with CHD but nearly three quarters of persons with early onset CHD; a positive family history of stroke was noted in 11% of families and accounted for 86% of early onset strokes. 18 On the other hand, only 1% of families carry a very strongly positive family history although these families account for 17% of cases of early onset CHD and 19% of cases of early onset strokes. 18 These data generate the hypothesis that rare "private" mutations in families with a very strongly positive family history may account for a small but significant minority of the cases of early onset CVD.
Common genetic variation in CVD
There is substantial evidence that heritable factors underlie the variation in clinical CVD, subclinical CVD and its risk factors in human populations. However, while pedigree studies often provide strong evidence for a Mendelian mode of transmission for rare familial CVD, the impact of a familial predisposition and the mode of transmission is often not apparent from studies of individual pedigrees for most cases of common, "complex" CVD like myocardial infarction. Studies of large groups of families or observational studies of family history have provided evidence for a familial predisposition to myocardial infarction, 19, 20 atrial fibrillation, 21, 22 and congestive heart failure. 23 Heritability-the proportion of interindividual phenotypic variation that is attributed to genetic variation among individuals -can be estimated in groups of siblings or other related family members. There is substantial evidence from multiple studies for moderate heritability (e.g., 30-50%) in the quantitative measurement of subclinical atherosclerosis, such as coronary artery calcification 24, 25 and carotid IMT. 26 Similarly, there is moderate heritability for traditional risk factor measures, such as systolic blood pressure, total cholesterol, and body mass index. Thus, the totality of evidence from studies of the familial predisposition for CVD and from heritability studies of the independent precursors of CVD suggests that genetic variation underlies a substantial proportion of CVD and its risk factors.
With the public availability of the complete human genome sequence came greater attention to the hypothesis that common genetic variants may underlie most common, complex diseases such as CVD. 26 Among the most common sources of genetic variation are single nucleotide polymorphisms (SNPs), occurring about every 1000 base pairs in the approximately 3 billion base pairs comprising the human genome sequence. A complete publicly available catalogue of SNPs has been made available and is being updated by the NIH-supported international HapMap Project (http://www.hapmap.org/). While there are likely >10,000,000 SNPs in the human genome, SNPs that reside nearby each other are highly correlated due to a lack of recombination (also known as 'linkage disequilibrium') within chromosomal segments. From detailed studies of linkage disequilibrium patterns, it appears that genotype scans of 300,000 to 500,000 SNPs spaced across the entire genome provide sufficient statistical power to define the majority of common genetic variation. 27 Greater numbers of SNPs are needed to define variation for populations of older ancestry, such as those of African ancestry, than for more recent populations, such those of European ancestry. 22 Technology development and competition has allowed the genotyping of thousands of SNPs using high throughput, multiplex SNP assays on genotyping chips.
Genomewide association studies
A genome-wide association study (GWAS) is a study of genetic variation across the entire human genome designed to identify genetic associations with observable clinical traits or with the presence or absence of a disease. A first demonstration that a GWAS could be used to identify genes predisposing to common disease was reported in 2005, when a GWAS using a first generation chip of 100,000 SNPs was used in a case-control study of fewer than 150 subjects to identify variation in the complement factor H (CFH) predisposing to agerelated macular degeneration. 28 The pooled estimate of multiple subsequent replication studies demonstrated unequivocally a consistent association with AMD of CFH variant. Since 2005, technology development and price reductions have led to several generations of DNA chips with higher densities, ranging from 300,000 to over 1,000,000 SNPs. Between 2006 and 2007, about ten published GWAS reports had appeared. Since 2006 to the present, over 150 GWAS reports have been published in the peer reviewed literature, reporting associations with a wide range of disease phenotypes of >300 SNP variants.
While many GWAS's for CVD are in progress and have yet to be reported, there are already several remarkable discoveries, through GWAS reports, of genetic variants associated with CVD and its risk factors. CVD outcomes studied by GWAS have included peripheral arterial disease, MI, stroke and atrial fibrillation. 29 Other GWAS phenotypes have included traditional CVD risk factors (including BMI and obesity, type 2 diabetes mellitus and fasting glucose, hypertension and systolic BP, nicotine dependence, as well as levels of LDL, HDL and triglycerides), QT interval length on ECG, inflammatory and hemostatic biomarkers, and imaging measures of subclinical atherosclerosis (including coronary artery calcium, carotid IMT) and left ventricular hypertrophy. 29 A few selected GWAS reports highlight some surprising findings. In one example, QT interval length on ECG was among the first CVD phenotypes to be studied by GWAS, revealing a strong association with SNPs in the CAPON gene in a staged study involving two independent cohorts 30 and subsequently independently replicated in another large cohort. 31 Unlike most genes known to be associated with QT interval length, CAPON does not encode an ion channel but rather is a regulator of nitric oxide synthase; its mechanism of prolonging the QT interval is unknown. In a second example, a recent GWAS report was undertaken to identify genetic determinants of alterations in LDL cholesterol, HDL cholesterol or triglycerides in three independent cohorts in which collaborators had recently identified new loci underlying type 2 diabetes mellitus. [32] [33] [34] Using an in silico meta-analysis of GWAS data from all three cohorts, common SNPs from 18 loci were associated with at least one of the lipid phenotypes. Of these loci, six were unexpected and had not been previously implicated in lipid physiology. 35 A risk score, using nine of previously identified LDL or HDL related SNPs, was tested for association with incident CVD; the risk score discriminated as well as but not better than clinical risk factors. 36 Finally, three independent GWAS studies recently reported strong evidence for an association of a region in chromosome 9p21 near the cyclindependent kinase inhibitor genes CDKN2A and CDKN2B [33] [34] [35] . However, the signal for association is in a region free of known protein-coding sequence, and, interestingly, one of the three new loci associated with type 2 diabetes mellitus is also in chr 9p21. [37] [38] [39] Several other loci are implicated but have somewhat lower strength of evidence for association with myocardial infarction. 40 The number of GWAS reports is increasing in an exponential manner and several common themes are emerging. First, because of the risk of false positive results from multiple testing, SNP associations must meet rigorous statistical thresholds to be considered "significant on a genomewide level". Remarkably, many of the initial GWAS association findings have been replicated, in a convincing manner, using modern, stringent guidelines. 41 Second, the magnitude of most SNP associations in GWAS is modest (relative risks of 1.2-1.4), as is the proportion of variation explained by individual SNPs, emphasizing the need for large sample sizes to discover true positive associations. Third, while a growing number of GWAS associations have confirmed previously reported associations using other methods, many loci discovered in GWAS are neither located in or near protein-coding genes, nor are they near genes previously known to be associated with the disease of interest. Thus, it appears that some genetic associations may be attributed to genetic mechanisms other than alterations in the sequence of protein-coding genes. Of interest, in a recent analysis of human gene expression, it was estimated that the majority of bases in the human genome are found in gene transcripts, including non-protein coding transcripts. 42 Fourth, it should be remembered that genetic associations from GWAS do not constitute the "causal" variant but rather are a marker of a probable nearby variant. Further resequencing and/or fine mapping of associated regions are indicated to isolate the functional variant(s). Fifth, a number of loci identified in GWAS are associated with several distinct diseases, suggesting pleiotropy. Finally, to date there have been very few studies that convincingly describe the biological function or deleterious effect of SNPs and/or genes identified through GWAS.
NHLBI genome programs and new research models
The NHLBI supports a robust portfolio of GWAS programs that provide population diversity and great depth and breadth of clinically relevant phenotypes ( Table 1 ). The NHLBI's position is that the greatest public benefit will be realized if data from GWAS are made available, under terms and conditions consistent with the informed consent provided by individual participants, in a timely manner to the largest possible number of investigators. Accordingly, the NHLBI has played a leadership role in the development of a trans-NIH data sharing policy for GWAS studies, effective January 25, 2008 (http://grants.nih.gov/grants/gwas/), and the NHLBI adheres strongly to this policy. Concurrent with development of the policy, the National Center for Biotechnology (NCBI) created a genotype-phenotype NIH database called dbGaP (database of genotype and phenotype). 43 The SNP Health Association Resource (SHARe) Program is the first NHLBI genomic program that now has data available for biomedical researchers. 44 The SHARe scientific resource draws genotyping of the three generations of participations in the NHLBI Framingham Heart Study, including 550,000 SNPs in over 9,400 consenting participants. The phenotype component includes >16,800 clinical variables, including risk factors, biomarkers, subclinical imaging measures, and clinical CVD as well as other chronic disease areas, such as bone density and dementia. Additional cohorts are planned for SHARe, including the SHARe Asthma Research Project (SHARP).
STAMPEED (SNP Typing for Association with Multiple Phenotypes from Existing
Epidemiologic Data) consists of 13 grants awarded to support GWAS in a wide range of cardiovascular, lung and related diseases. Nearly 40,000 male and female participants are included with substantial representation from minority populations. In the Candidate Gene Association Resource (CARe), a GWAS is now underway in over 10,000 African American subjects from five NHLBI supported population cohorts to study a range of cardiovascular phenotypes. The ENDGAME (Enhancing Development of Genome-Wide Association Methods) program supports eleven teams of investigators to develop innovative strategies and tools for planning, initiating, conducting, and analyzing genome-wide association studies. All strategies and tools developed through these awards will be made available to the scientific community. In its totality, with ongoing or planned GWAS, the NHLBI portfolio will study well over 100,000 research participants from multiple, diverse and wellphenotyped disease cohorts and population cohorts.
Observations from GWAS studies to date and the robust portfolio of ongoing GWAS suggest a number of immediate next steps for genomewide association studies ( Figure 2) . First, the availability of data for sharing will increase the opportunities for a broad diversity of scientists to make new discoveries. Second, collaboration between multiple GWAS will be necessary to convincingly replicate genetic associations and exploit the power of individual GWAS. The aforementioned consortia of researchers studying the genomics of type 2 diabetes mellitus and the Wellcome Trust Case Control Consortium (WTCCC) represent two successful models of genomics collaboration focused on one or a few diseases. In one newly formed consortium, the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) Consortium, GWAS results are being systematically pooled in a series of in silico meta-analyses from five prospective, population-based cohorts to study GWAS associations across over twenty different phenotype areas in CVD, aging and multiple other chronic diseases. 45 Third, the functional significance of GWAS associations must be defined, affording great opportunity for collaboration between bench scientists, statisticians, epidemiologists, and clinical investigators. Moreover, functional genomics requires animal and human tissue models and systems biology approaches that utilize proteomics, metabolomics, and gene expression profiling. Finally, as sequencing cost decreases and accuracy improves, deep sequencing of ever larger proportions of the human genome with follow providing the opportunity to define the totality of common, less common and rare variation underlying CVD. The scientific opportunities have never been greater to unravel the mystery of genetic predisposition to CVD.
Conclusion
The NHLBI supports a large portfolio of population based genetic and genomic programs in diverse US populations. We are strongly committed to making participant level data and aggregate research results available to a broad community of investigators, while protecting the privacy and confidentiality of study participants. An abundance of knowledge regarding the Mendelian forms of CVD exists; yet, the current explosion of genomewide association studies is leading to a remarkable pace of discovery regarding highly prevalent cardiovascular risk factors and common, clinically apparent CVD. These discoveries represent only "the end of the beginning". The next phase of discovery will require deep sequencing of the human genome, functional research in animal and human models, and application to clinical medicine. Timeline of NHLBI genetic and genomic investigations for rare and common diseases, taking advantages of advances in the Human Genome Project and other technologies. NHLBI Strategic Plan for translating genomic discoveries to clinical medicine. The NHLBI goal is to capitalize on the rich scientific knowledge to predict risk for disease, prevent its onset, and personalize diagnostic and therapeutic care. Up to 28,000 women participants in the Women's Health Study, a study cohort which has been followed for over a decade as part of a randomized controlled study for prevention of cardiovascular disease and cancer.
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